

Robust Pipeline of Investigational Candidates

Modality Key:



Small Molecule



Peptide



Antibody



Gene Therapy

Therapeutic Area Key:

● Psychiatry

● Neurology

● Endocrinology

● Immunology

Study Initiating



NBIB-'223 (Frataxin)

Friedreich's Ataxia



NBI-'188 (CRF₁ Antagonist)

Women's Health



NBIM-'1748 (Undisclosed)

Immunology

Phase 1



NBI-'569* (M1/M4 Agonist)

Alzheimer's Psychosis



NBI-'675 (VMAT2 Inhibitor)

CNS Indications



NBI-'355 (Nav1.2/1.6 Inhibitor)

Epilepsy



NBI-'567*± (M1 Preferring Agonist)

Alzheimer's Cognition



NBI-'986 (M4 Antagonist)

Movement Disorders



NBIP-'1435 (CRF₁ Antagonist)

Classic Congenital Adrenal Hyperplasia



NBIP-'2118 (CRF₂ Agonist)

Obesity



NBIP-'1968 (TG + NBIP-'2118 Combo)

Obesity



NBIM-'1112 (Undisclosed)

Immunology



NBIM-'1008 (Undisclosed)

Immunology

Phase 2



direclidine* (M4 Agonist)

Bipolar Mania



NBI-'570* (M1/M4 Agonist)

Schizophrenia



NBI-'890 (VMAT2 Inhibitor)

Tardive Dyskinesia

Phase 3



direclidine* (M4 Agonist)

Schizophrenia



osavampator^{II} (AMPA PAM)

Major Depressive Disorder

Neurocrine Biosciences has global rights, unless otherwise noted.
Investigational therapies are not approved for use in any country

*Licensed from Nxera Pharma.

±Nxera Pharma has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

^{II}Takeda Pharmaceutical Company Limited has retained rights in Japan.

CRF2 = Corticotropin Releasing Factor 2; TG= Neurocrine Proprietary GIP-GLP-1-Preferring Triple Agonist ("Light" on Glucagon Activity); CRF1 = Corticotropin Releasing Factor 1; M1 = M1 Muscarinic Receptor; M4 = M4 Muscarinic Receptor; VMAT2 = Vesicular Monoamine Transporter; CNS = Central Nervous System; Nav = Sodium Channel; AMPA PAM = alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid Positive Allosteric Modulator

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CP-NBI-US-0449v14 08/2026